ArticleUpdates in surgery2026
Development of a prognostic model based on positive lymph node ratio for yp stage III colorectal cancer.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For locally advanced rectal cancer and potentially resectable T4bM0 colon cancer, neoadjuvant therapy improves remission rates and resectability. However, conventional TNM staging often fails to predict prognosis in ypIII CRC patient's post-neoadjuvant therapy due to lymph node regression (particularly when < 12 nodes are detected). We evaluated the prognostic value of positive lymph node ratio (LNR) in this cohort.Retrospective analysis of 489 ypIII CRC patients treated with neoadjuvant therapy and radical surgery (2008-2018). Optimal LNR cutoff for disease-free survival (DFS) was determined using R software. Patients were stratified into low/high-LNR groups. Clinicopathological characteristics and DFS were compared. A COX regression-based nomogram incorporating LNR was developed and externally validated against TNM staging via ROC analysis.LNR optimal threshold was 0.29 (low: ≤ 0.29, n = 317; high: > 0.29, n = 172). High LNR predicted shorter DFS (HR = 2.103, 95% CI 1.582-2.796, P < 0.0001) and was an independent prognostic factor (multivariate HR = 1.825, 95% CI 1.391-2.394, P < 0.001). The LNR-integrated nomogram outperformed TNM staging in predicting DFS (AUC: 0.852 versus 0.781, P < 0.05).LNR is an independent prognostic factor for ypIII CRC. Supplementing TNM staging with LNR enhances prognostic accuracy.
Indexed as
Identifiers
40549299What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.